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Baseline residual kidney function (RKF) and its rate of decline during follow-up are pur-
ported to be reliable outcome predictors of patients undergoing Peritoneal Dialysis (PD).
The independent contribution of each of these factors has not been elucidated.
Method
We report a multicenter, longitudinal study of 493 patients incident on PD and satisfying two
conditions: a glomerular filtration rate (GFR)1 mL/minute and a daily diuresis300 mL.
The main variables were the GFR (mean of urea and creatinine clearances) at PD inception
and the GFR rate of decline during follow-up. The main outcome variable was patient mor-
tality. The secondary outcome variables were: PD technique failure and risk of peritoneal
infection. The statistical analysis was based on a multivariate approach, placing an empha-
sis on the interactions between the two main study variables.
Main Results
Baseline GFR and its rate of decline performed well as independent predictors of both
patient mortality and risk of peritoneal infection. These two main study variables maintained
a moderate correlation with each other (r2 = 0.12, p<0.0005), and interacted clearly, as pre-
dictors of patient mortality. A low baseline GFR followed by a fast decline portended the
worst survival outcome (adjusted HR 3.84, 95%CI 1.81–8.14, p<0.0005)(Ref. baseline GFR
above median plus rate of decline below median). In general, the rate of decline of RKF had
a greater effect on mortality than baseline GFR, which had no detectable effect on survival
when the decline of RKF was slow (HR 1.17, 95% CI 0.81–2.22, p = 0.22). Conversely, a rel-
atively high GFR at the start of PD still carried a significant risk of mortality, when RKF
declined rapidly (HR 1.89, 95% CI 1.05–3.72, p = 0.028).
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Conclusion
The risk-benefit balance of an early versus late start of PD cannot be evaluated without tak-
ing into consideration the rate of decline of RKF. This circumstance may contribute to
explain the controversial results observed at the time of evaluating the potential benefits of
an early initiation of PD.
Introduction
Preservation of residual kidney function (RKF) facilitates management and improves quality of
life of patients treated with chronic peritoneal dialysis (PD). The residual function permits an
incremental dosing of PD, which is generally easier to reconcile with the lifestyle of the patients
[1], and improves toxin removal and volume control, compared to PD alone [2]. Many obser-
vational studies have shown that sustained RKF improves both patient and PD technique sur-
vival [3], and has a beneficial effect on other complications of chronic kidney disease and PD
therapy, such as cardiovascular disease, disorders of bone and mineral metabolism, inflamma-
tion and malnutrition [2].
Previous studies investigating the prognostic value of RKF in PD patients have defined this
study variable in different ways, including baseline [4–8] and mean [4,7,9] GFR levels, GFR val-
ues antedating selected outcomes [8] or time-dependent strategies [10–13]. Some of these stud-
ies have restricted their analyses to patients starting PD, while others have also recruited
established PD patients. There is a remarkable paucity of studies comparing the prognostic
importance of baseline RKF and its time course during follow-up. It is clear that these variables
may influence independently the outcome of PD patients, but it is also conceivable that they
have interactive outcome effects. If so, the interaction could help to explain the variable effect
of early initiation on the outcome of PD [14,15].
To test this hypothesis, we have undertaken a multicenter, observational study, comparing




We analyzed a historic cohort of patients placed on PD therapy in four Spanish units during
the period extending since January 2000 to December 2010, using a multicenter, observational
design. The main objective of the study was to establish the prognostic value of both the base-
line levels and the rate of decline of RKF during follow-up (main study variables). The main
outcome variable was patient mortality. Secondary outcome variables included PD technique
failure (defined by drop-out to hemodialysis therapy for at least 90 days) and the rate of perito-
neal infection (survival to first episode). We took into consideration the main control variables
with a claimed effect on the selected outcomes (see below).
The study complied with the ethical conditions stipulated by the participating centers for
retrospective observational studies. The Institutional Investigation Committees of the Univer-
sity Hospital Puerta Real (Cadiz) and of the regional Government of Asturias (Spain) evaluated
and approved the study protocol. Approval by these committees requested oral informed con-
sent from the participants who were accessible at the time the study was initiated. This consent
was registered in the clinical records of the patients.
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Study population
We included in our analysis all the consecutive cases from the clinical records of the participat-
ing units that fulfilled the following inclusion/exclusion criteria:
1. Age older than 10 years at the inception of PD
2. Chronic kidney disease stage 5d
3. Patients incident on PD, either primarily or following hemodialysis therapy or a failed kid-
ney transplant
4. Minimum follow-up of 6 months on PD
5. Estimations of RKF available at least at baseline and after 6 months on PD
6. Baseline 24-hour urine volume300 mL/24 hours and estimated glomerular filtration rate
(GFR)1 mL/minute
7. Full clinical records available
Study variables and data analysis
As previously stated, study variables were baseline RKF and its rate of decline after PD was
started. We estimated RKF from the mean of urea and creatinine renal clearances (GFR), at
inception of PD (meaning less than one month after initiation of dialysis) and then after 6, 12
and 24 months of PD therapy. We estimated the rate of decline of RKF by calculating the dif-
ference between its baseline value and that observed at the time of the last available estimation
of GFR (6, 12 or 24 months), and then dividing it by the time of follow-up (months).
Control variables included a wide set of demographic, clinical, biochemical, adequacy and
prescription factors, shown in Tables 1 and 2. Body mass index was calculated as body weight
(Kg) / Height2 (m). Charlson’s score was used to categorize general comorbidity at the initia-
tion of PD. Biochemical determinations were produced mostly with the help of autoanalyzers.
C reactive protein levels were estimated by immunoturbidimetry.
Basic univariate data analysis was produced using common parametric (Student’s t test,
ANOVA, repeated measures) and nonparametric (χ2 distribution, Mann Whitney, Spearman)
tests, as appropriate. Univariate survival analyses were generated according to Kaplan Meier
plots (log rank test), after categorizing baseline GFR according to median values and its time
course by tertiles. Multivariate analysis was based on baseline and time-dependent Cox’s mod-
els. Patients were censored in cases of kidney transplant, dialysis withdrawal after improvement
of GFR, loss to follow-up, drop-out to hemodialysis (patient survival and peritoneal infection)
and demise (technique failure and peritoneal infection).
To explore the effects of baseline and RKF changes, we analyzed their contributions as inde-
pendent variables in the general Cox’s model. We applied interaction terms to scrutinize poten-
tial effect modifications among the main study variables. When statistical significance was
reached, we performed additional stratified analyses, to clarify the significance of the findings.
We used the SPSS 19.0 and Stata v.10 softwares for data management.
Results
1. Overview
Six hundred and two patients were pre-selected for the study, but 109 were finally excluded,
because they did not fulfill the pre-established criteria for baseline GFR (n = 62) or because of
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inconsistencies or gaps in their clinical records (n = 40). The study population thus included
493 patients, of whom 287 (58.2%) completed at least 24 months of follow-up (mean
29.9 ± 19.8 months). The main baseline demographic, clinical and time-dependent variables
are presented in Tables 1 and 2. Baseline GFR showed a moderate, but significant correlation
with its ensuing rate of decline (Fig 1, r2 = 0.12, p<0.0005). The mean rate of decline of GFR
was 0.13 ± 0.23 mL/minute/month (range -1.23 to 1.17). In 90 cases (18.2%) GFR was higher at
the end of follow-up (6–24 months) than at baseline, although only in 24 of them (4.9%) the
slope of recovery was faster than 0.2 mL/minute/month.
At the end of follow-up, 149 patients (30.2%) had died. The main causes for death included
cardiovascular events (n = 66) and infections (n = 27); 17 patients died for unknown causes.
Sixty-nine patients (14.0%) switched to hemodialysis during follow-up; peritoneal infections
(n = 27) and inadequacy of PD (n = 16) were the main quoted causes. One hundred and thirty-
four patients (27.2%) were censored after undergoing kidney transplantation. One hundred
and eighty-eight patients (38.5%) suffered at least one peritoneal infection during follow-up,
for a total of 574 episodes (incidence: one episode every 25.7 patient-months).
Table 1. Clinical and demographic characteristics of the study population.
Age (years) 58.1±15.8







Diabetic nephropathy 144 (29.2)
Other/Unknown 135 (27.4)
Diabetes mellitus (%) 189 (38.3)
Body mass index (Kg/m2) 26.8 ± 4.8
Origin (%)
Incident on renal replacement therapy 454 (92.1)
Hemodialysis 22 (4.5)
Failed kidney transplant 17 (3.4)
Charlson’s comorbidity score 4.5 ± 2.2
Systolic blood pressure (mm Hg) 136.0 ± 20.4
Diastolic blood pressure (mm Hg) 77.0 ± 12.7
Hemoglobin (g/dL) 11.3 ± 1.6
Plasma albumin (g/L) 36.5 ± 5.3
Plasma cholesterol (mg/dL) 174.4 ± 50.3
C reactive protein (mg/dL) 0.50 (0.24/1.20)
GFR (mL/minute) 7.5 ± 3.3
Diuresis (mL/24 hours) 1437 ± 665
Proteinuria (g/24 hours) 1.7 ± 2.4
D/P creatinine at 240’ (baseline PET) 0.66 ± 0.13
Modality of PD at inception (CAPD/APD)(%) 368/125 (74.6/25.4)
Type of PD solution (low GDPs)(%) 187 (38.2)
Continuous variables expressed as mean ± SD, except C reactive protein (median with interquartile range).
Categorized variables expressed as number of cases (%). GFR: Glomerular ﬁltration rate (mean of urea and
creatinine renal clearances). PET: Peritoneal equilibration test. GDPs: Glucose degradation products.
doi:10.1371/journal.pone.0158696.t001
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2. Patient mortality
Univariate analysis demonstrated that both baseline GFR (Fig 2) and its rate of decline while
on PD (Fig 3) correlated with patient mortality. The general Cox’s model confirmed that both
variables had an independent effect on mortality (Table 3). Remarkably, we observed a signifi-
cant interaction between the main study variables, at the time of predicting mortality
(p = 0.043 for the interaction term). Subsequent stratified analysis showed that baseline GFR
was a predictor of mortality only if its subsequent decline while on PD was relatively rapid. In
contrast, the negative prognostic significance of a fast decline of GFR was more apparent if the
Table 2. Study population. Time-dependent variables.
Baseline 6 months 12 months 24 months
N 493 493 419 287
Modality of PD (patients on automated PD)(%) 125 (25.2) 161 (34.3) 161 (38.4) 120 (42.0)
Peritoneal glucose load (g/24 hours) 90 ± 39 97 ± 48 102 ± 53 114 ± 61
Icodextrin for long dwell (%) 287 (58.6) 308 (65.7) 283 (67.9) 197 (69.9)
Number of antihypertensives 1.7 ± 1.1 1.7 ± 1.2 1.7 ± 1.2 1.6 ± 1.2
RAS antagonists (%) 222 (45.3) 212 (44.9) 189 (46.0) 125 (44.0)
Dose of furosemide (mg/24 hours) 37.1 ± 44.6 62.7 ± 60.8 72.0 ± 66.6 70.4 ± 68.9
Systolic BP (mm Hg) 136 ± 19 134 ± 19 133 ± 18 132 ± 18
Diastolic BP (mm Hg) 77 ± 12 76 ± 11 75 ± 11 74 ± 10
D/P creatinine 240’ 0.66 ± 0.13 - 0.67 ± 0.12 0.66 ± 0.13
Ultraﬁltration (mL/24 h) 888 ± 778 982 ± 655 1040 ±626 1118 ± 632
GFR (mL/minute) 7.5 ± 3.3 6.8 ± 3.6 5.7 ± 3.8 4.6 ± 3.9
Proteinuria (gr/24 h) 1.7 ± 2.4 - 1.0 ± 1.3 0.8 ± 1.1
Continuous variables denote mean (SD), Categorized variables denote number of cases (%). RAS: Renin-angiotensin system. BP: Blood pressure. D/P:
Quotient dialysate/plasma. GFR: Glomerular ﬁltration rate (mean of urea and creatinine renal clearances). Bold characters indicate signiﬁcant differences
versus baseline
doi:10.1371/journal.pone.0158696.t002
Fig 1. Correlation between baseline GFR and its rate of decline during follow-up on PD.
doi:10.1371/journal.pone.0158696.g001
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initial RKF was relatively poor (Table 3). The association of a baseline GFR below median and
a pace of decline above median were the worst combination for expected survival (Table 4).
The risk of mortality was indeed increased in any setting where GFR decreased rapidly, even if
baseline RKF was relatively good. On the contrary, a baseline GFR below median did not por-
tend a poor prognosis, provided that its rate of decline was slow or negative (Table 4).
Fig 2. Patient survival according to baseline GFR, categorized frommedian value. Kaplan Meier plot
(log rank).
doi:10.1371/journal.pone.0158696.g002
Fig 3. Patient survival according to tertiles of the rate of decline of GFR during follow-up. Kaplan Meier
plot (log rank).
doi:10.1371/journal.pone.0158696.g003
Residual Kidney Function in PD
PLOSONE | DOI:10.1371/journal.pone.0158696 July 8, 2016 6 / 11
Incidentally, we did notice a significant interaction between age and the rate of decline of GFR
(p = 0.032 for the term), suggesting that the impact of the latter variable on mortality was
greater in younger (<65 years) (hazard ratio HR 1.08 per year, 95% confidence interval CI
1.04–1.11, p<0.0005) than in older (>65 years) patients (HR 1.04, 95% CI 0.99–1.07,
p = 0.068).
Time-dependent Cox’s model confirmed that GFR, when managed as a time-dependent
variable, was an independent predictor of patient mortality (Table 5).
3. PD technique failure
Our analysis confirmed the well known difficulties involved in the development of predictive
models for PD technique failure. Univariate analysis did not show a significant effect of base-
line GFR (p = 0,68 log rank test), and just a trend without significance (p = 0.08) for its rate of
decline. General Cox’s model (Table 6) did show a modest effect of the pace of decline of RKF,
which was the only identifiable, independent predictor of technique failure, with a minor trend
for baseline GFR to have a similar effect (p = 0.22 for the interaction term). Time-dependent,
multivariate analysis was consistent with these observations (Table 6).
Table 3. Predictors of mortality of patients starting PD. Multivariate analysis.
HR 95% CI P
Age (x year) 1.05 1.03–1.06 <0.0005
Charlson’s score (x point) 1.22 1.10–1.37 <0.0005
Diabetes 1.69 1.15–2.48 0.007
Plasma albumin (x g/L) 0.95 0.92–0.98 0.003
Hemoglobin (x g/dL) 0.88 0.77–1.00 0.053
Peritoneal transport (PET)(x 0,1) 1.02 1.00–1.04 0.007
Rate of decline of GFR (x mL(/min/month) 1.91 1.43–2.56 <0.0005
Baseline GFR above median 1.82 0.92–3.60 0.08
Baseline GFR below median 2.55 1.50–4.34 0.001
Baseline GFR (x mL/min) 0.90 0.84–0.97 0.005
Rate of decline faster than median 0.84 0.75–0.93 0.002
Rate of decline slower than median 0.96 0.88–1.06 0.96
General Cox’s model. Dependent variable: Mortality (any cause). GFR: Glomerular ﬁltration rate (mean of
urea and creatinine renal clearances). PET: Peritoneal equilibration test. For baseline GFR and its rate of
decline, we present the general coefﬁcients of the model, and then stratiﬁed values, to facilitate clinical
interpretation of the interaction between both variables.
doi:10.1371/journal.pone.0158696.t003
Table 4. Combined effect of baseline GFR and its rate of decline onmortality during follow-up on PD.
Stratified analysis.
n Unadjusted Adjusted*
HR (95% CI) p HR (95% CI) p
High baseline GFR & Slow decline 97 1 (Ref) 1 (Ref)
High baseline GFR & Fast decline 150 1.78 (0.99–3.37) 0.065 1.89 (1.05–3.72) 0.028
Low baseline GFR & Slow decline 149 1.55 (0.78–3.08) 0.35 1.17 (0.81–2.22) 0.22
Low baseline GFR & Fast decline 97 3.23 (1.66–6.28) 0.001 3.84 (1.81–8.14) <0.0005
Baseline GFR and rate of decline categorized from median values. GFR: Glomerular ﬁltration rate (mean of
urea and creatinine renal clearances).
* Control variables: Age, Charlson’s score, diabetes, plasma albumin and peritoneal transport rate
doi:10.1371/journal.pone.0158696.t004
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4. Risk of peritoneal infection
Univariate analysis demonstrated a significant association between baseline GFR and the risk
of peritoneal infection (p = 0.032, log rank test), with a similar trend (p = 0.068) for the rate of
decline of RKF. General Cox’s model identified both baseline GFR (HR 0.94 per mL/minute,
95% CI 0.90–0.98, p = 0.008) and its rate of decline during follow-up (HR 2.08 per mL/minute/
month, 95% CI 1.08–4.02, p = 0.028) as independent predictors of the risk of peritoneal infec-
tion (p = 0.75 for the interaction term), after controlling for other independent predictors of
this complication (age, plasma albumin and C reactive protein). Time-dependent GFR was not
a predictor of the risk of peritonitis (adjusted HR 1.06, 95% CI 0.99–1.15, p = 0.11). We did not
detect interactions between GFR and age, serum levels of albumin, C reactive protein or modal-
ity of PD, as predictors of peritoneal infection.
Discussion
The results of our study demonstrate that baseline GFR and its rate of decline during follow-up
are independent predictors of outcome in patients starting PD therapy. As expected, baseline
GFR and its rate of decline correlated, one positively and the other negatively, with mortality.
A high baseline GFR portended a relatively fast decline in renal function, during follow-up (Fig
1). This type of correlation has been observed in some previous studies [13,16,17] and that can
be explained, at least partly, as a mathematical consequence of expressing the decline of GFR in
absolute terms. Consistent with this interpretation, a complete loss of RKF during follow-up is
less likely if the baseline GFR is high [17–20].
Table 5. Predictors of mortality of patients starting PD. Time-dependent multivariate analysis.
HR 95% CI p
Age (x year) 1.06 1.04–1.07 <0.0005
Charlson’s score (x point) 1.07 0.98–1.18 0.18
Diabetes 1.80 1.21–2.66 0.003
Plasma albumin (x g/L) 0.94 0.91–0.97 <0.0005
Hemoglobin (x g/dL) 0.82 0.71–0.92 0.001
Peritoneal transport (x point) 1.01 1.00–1.03 0.07
Proteinuria (x g/24 hours) 1.09 0.04–0.15 0.001
GFR, time-dependent (x mL/min) 0.99 0.99–1.00 0.011
Event peritonitis, time dependent 1.00 1.00–1.00 0.74
Time-dependent Cox’s model. Outcome variable: mortality (any cause). Other time-dependent variables
scrutinized not signiﬁcant. GFR: Glomerular ﬁltration rate (mean of urea and creatinine renal clearances).
doi:10.1371/journal.pone.0158696.t005
Table 6. Predictors of PD technique failure. General and time-dependent multivariate analyses.
Adjusted HR 95% CI P
General model
Baseline GFR (x mL/min) 0.92 0.84–1.01 0.083
Rate of decline of GFR (x mL/min/month) 1.49 1.01–2.20 0.043
Time-dependent model
Age (x year) 0.98 0.964–0.99 0.015
GFR, time-dependent 0.99 0.991–1.00 0.060
Outcome variable: PD technique failure (drop-out to hemodialysis). GFR: Glomerular ﬁltration rate (mean of
urea and creatinine clearances).
doi:10.1371/journal.pone.0158696.t006
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More surprisingly, we detected a significant interaction between the effects of baseline GFR
and its rate of decline on mortality. Considered in clinical terms, a higher baseline GFR offered
a survival advantage only if the ensuing rate of GFR decline was indolent. A low baseline GFR,
however, amplified the negative effect of a fast rate of GFR decline, during follow-up. Overall,
stratified analysis of our data (Table 4) suggests that a fast decline of GFR is more consequen-
tial than baseline GFR as a predictor of mortality, because patients who started PD with a lower
level of GFR, but experienced a slow rate of GFR decline during follow-up, did not have a
greater risk of mortality. These findings confirm the independent effect of these study variables,
but also the need to consider their interaction, for survival analyses.
Patient mortality was the outcome most clearly influenced by the study variables (Tables 3
to 5). This finding agrees with a majority of previous studies on this question [4–12]. Interac-
tion analysis also revealed that the rate of decline of GFR had a more apparent influence on the
risk of mortality in younger patients. This finding may be explained by the confounding effects
of aging itself or its related comorbidities on survival.
Our data confirm the difficulties involved in modeling PD technique failure (Table 6), as
reported by in previous studies [12,13]. Even when these difficulties are considered, baseline
GFR and, particularly, its rate of decline performed well as consistent predictors of PD tech-
nique failure. This finding is not unexpected, because RKF mitigates the effects of the main
complications resulting in PD drop-out [1]. For instance, RKF permits incremental dosing of
PD, optimizing quality of life and reducing technique drop-out for social reasons. In addition,
RKF helps to prevent dialysis inadequacy, volume overload, peritoneal membrane injury
(lower peritoneal glucose load) and peritoneal infections. The results of our study indeed agree
with previous reports suggesting an association between RKF and the risk of peritoneal infec-
tion [21]. This notwithstanding, we were unable to confirm this association using a time-
dependent approach. The explanation for this discrepancy is not clear, although the relation-
ship between RKF and peritoneal infection may be complex and bidirectional, because perito-
neal infections may themselves accelerate the rate of decline of GFR (Table 5) [22–24].
Remarkably, aminoglycosides were not routinely used for the treatment of peritonitis in any of
the participating centers.
The last decade has seen substantial controversy, regarding the advantages of an early versus
late initiation of dialysis therapy. In general, observational studies of hemodialysis patients
have shown an association between early start and increased mortality, during follow-up [14].
The interpretation for this unexpected finding is not totally clear. Hemodialysis therapy itself
may carry negative effects for many patients, including an accelerated decay of RKF. The para-
dox, however, is commonly attributed to study selection biases, because early start of dialysis is
more likely in high risk patients, where other comorbidities may conceal any positive effect of
RKF on survival. Studies focusing exclusively on patients beginning PD therapy generally show
a beneficial effect of doing so while the level of RKF is still high [14]. The reasons for the dis-
crepancy between hemodialysis and PD are, once again, unclear. Differences in predialysis
management could bear some influence, because the selection bias for early start may be less
for PD than for hemodialysis patients. Additionally, incremental PD prescription may help
prevent some adverse effects of hemodialysis therapy. In particular, a slower decline of RKF [1]
could augment the potential benefits of starting dialysis at relatively high levels of GFR. A third
explanation may lie with the different methods used to quantify GFR. In general, studies on PD
patients tend to use the mean of urea and creatinine renal clearances, for this purpose. Studies
on hemodialysis patients, on the other hand, calculate GFR from estimative, creatinine-based
formulas, which tend to overestimate GFR in patients with a low muscle mass [25]. Notably,
the randomized trial IDEAL was unable to demonstrate a prognostic significance for RKF at
the initiation of dialysis [26], either in patients on hemodialysis or PD [15]. The results of this
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study, however, are also inconclusive, because of methodologic limitations, that include estima-
tion of GFR according to the Cockroft-Gault formula and a high incidence of protocol
violations.
The main limitation of our study resides with its retrospective, nonrandomized design. Sta-
tistical power was limited, particularly when it came to perform some subanalyses. Follow-up
for GFR was closed at 24 months because, the number of subjects lost to follow-up limited the
reliability of data. The main target of this study was to characterize simultaneously the prog-
nostic significance of baseline and evolutionary GFR. Consequently, only patients with a signif-
icant RKF at the initiation of PD (arbitrarily set at1 mL/minute). This peculiarity of the
study design must be taken into account when comparing our results with those from other
studies that included patients who were oligoanuric since inception of PD. Among its
strengths, our study had a multicenter design, included thorough clinical information and pro-
vided well-defined results, that allowed us to address the question we set off to answer.
In summary, RKF at the initiation of PD and its rate of decline during follow-up are inde-
pendent predictors of mortality, technique failure and peritoneal infection. These two variables
maintain a moderate correlation, and interact clearly at the time of predicting patient survival.
Our results indicate that the rate of decline of GFR has greater influence on mortality. In fact, a
lower baseline RKF does not portend mortality as long as GFR decreases slowly. Overall, the
survival benefit of early PD initiation cannot be evaluated without taking into consideration
the rate of decline of RKF, a principle that may help explain the variable effects of early PD
reported in the literature.
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